Evidence has suggested that rs3846662, a polymorphism in the HMG-CoA reductase gene, is a genetic modifier for the risk, age of onset and conversion of AD, and to a greater extent in ApoE4 carriers [66], supporting the involvement of HMG-CoA reductase in the effect of statins in AD. This evidence concerns the gene HMGCR and Alzheimer disease.